Acutaas Chemicals (ACUTAAS) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue grew 17.3% year-over-year to INR 2,072 million, led by advanced pharmaceutical intermediates and supported by PMDA GMP certification of both pharma facilities.

• Strong demand in pharmaceuticals, battery chemicals, and semiconductors, with new product introductions and customer contracts in export markets.

• Entered a joint venture in South Korea (Indichem) for specialty semiconductor chemicals, investing KRW 30 billion for a 75% stake, with commercial production expected by late 2026 or early 2027.

• Unaudited standalone and consolidated financial results for Q1 FY26 were approved by the Board and reviewed by statutory auditors with no modifications.

• Company name changed from Ami Organics Limited to Acutaas Chemicals Limited effective May 15, 2025.

Financial highlights

• Q1 FY26 consolidated revenue from operations was ₹20,723.72 lakhs, up from ₹17,667.09 lakhs in Q1 FY25; EBITDA was INR 50.9 crore, up 72.4% YoY; PAT was ₹4,401.05 lakhs, up 199.6% YoY.

• Gross margin expanded by 1,117 bps YoY to 53.2%, driven by cost optimization and improved product mix.

• EBITDA margin rose to 24.6% from 16.7% YoY.

• Net cash and cash equivalents stood at INR 270 crore; operating cash flow was INR 94.6 crore.

• Basic and diluted EPS (consolidated) for Q1 FY26 was ₹5.41, up from ₹1.83 in Q1 FY25.

Outlook and guidance

• Management targets 25% revenue growth for FY26 with improved margins, citing strong momentum and new market opportunities.

• Sequential revenue and margin improvement anticipated through the year, with Q1 typically being the softest quarter.

• Full benefit of new solar power plant to be realized from Q3 FY26.